Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog

ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP-1 Analog Aimed at
Improving Glycemic Control in Adults with Type 2 Diabetes

JERUSALEM, September 9 /PRNewswire-FirstCall/ -- Oramed Pharmaceticals,
Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery systems, announced
today that it has received approval from the Institutional Review Board (IRB)
to commence human clinical trials of an oral GLP-1 Analog. This approval was
granted after successful pre-clinical results were reported. The trials will
be conducted on healthy volunteers at Hadassah University Medical Center in
Jerusalem.
Currently, all GLP-1 Analogs are only available as injections. The oral
administration of GLP-1 Analogs may convey physiological advantages for
diabetic patients, as the hormone mimics the physiological route of incretin
absorption.
GLP-1 Analogs belongs to the Incretin family of drugs which have
pleiotropic effects desirable in the management of diabetes. Among the more
important effects are the insulinotropic effects and resultant reduction in
blood glucose levels, the inhibition of glucagon secretion and the
restoration of beta cell mass. GLP-1 Analogs are also associated with weight
loss, which is very desirable in patients with diabetes.
"The move from preclinical trials to human clinical trials of ORMD-0901
marks a strategic milestone for the company. We have expanded our platform
technology and will now have the opportunity to demonstrate its effectiveness
in another important family of polypeptide drugs for diabetes, which is
currently only available in injection form," said Oramed CEO Nadav Kidron.
Oramed is currently conducting Phase 2b clinical trials of its flagship
product, ORMD-0801, an oral insulin capsule.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top research scientists at Jerusalem's Hadassah
Medical Center. The Company's corporate and R&D headquarters are based in
Jerusalem.
For more information, please visit http://www.oramed.com
Forward-looking statements
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks
and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's ability to
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to the company's filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of the company
to differ materially from those expressed or implied in such forward looking
statements. The company undertakes no obligation to update or revise any
forward-looking statements.
Company and Investor Relation Contacts:
Oramed Pharmaceuticals, Inc.
Tara Horn
Cell: +972-54-334-4318
Office: +972-2-566-0001
Email: tara@oramed.com
http://www.oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Company and Investor Relation Contacts: Oramed Pharmaceuticals, Inc., Tara
Horn, Cell: +972-54-334-4318, Office: +972-2-566-0001, Email: tara@oramed.com,
http://www.oramed.com